Krystal Biotech Netherlands

Company snapshot

A commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines for high unmet medical needs.

• 1 approved product(s) across US/EU regulatory metadata.
• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Krystal Biotech Netherlands. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Krystal Biotech Netherlands.

1. Jun 8, 2026 Clinical update

   Topical Beremagene Geperpavec — Phase 3

2. Jun 8, 2026 Clinical update

   Open Label Topical Beremagene Geperpavec (B-VEC) — Phase 3

3. Jun 8, 2026 Clinical update

   Mebendazole — Phase 2

4. Jun 5, 2026 Clinical update

   KB803 — Phase 3

5. Jun 5, 2026 Clinical update

   KB408 (Nebulization) — Phase 1

View all clinical trial activity →

• What is Krystal Biotech Netherlands?

  Krystal Biotech Netherlands is a biotech organization headquartered in Pittsburgh, USA. It trades on NYSE under ticker KRYS. Primary therapeutic focus areas include Dystrophic Epidermolysis Bullosa, Autosomal Recessive Ichthyosis, TGM-1 Related Autosomal Recessive Congenital Icht

• Is Krystal Biotech Netherlands publicly traded?

  Yes. Krystal Biotech Netherlands is listed with ticker KRYS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Krystal Biotech Netherlands develop or market?

  We link 7 drug profile(s) where Krystal Biotech Netherlands is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/krystal-biotech#company-drugs.

• What are the latest developments for Krystal Biotech Netherlands?

  In the last 12 months our linked public records show 14 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Krystal Biotech Netherlands focus on?

  Krystal Biotech Netherlands focuses on Dystrophic Epidermolysis Bullosa, Autosomal Recessive Ichthyosis, TGM-1 Related Autosomal Recessive Congenital Ichthyosis based on our analysis of their pipeline programs and drug development activities.